| 000 | 01851 a2200577 4500 | ||
|---|---|---|---|
| 005 | 20250518070722.0 | ||
| 264 | 0 | _c20201001 | |
| 008 | 202010s 0 0 eng d | ||
| 022 | _a2326-6074 | ||
| 024 | 7 |
_a10.1158/2326-6066.CIR-19-0398 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHan, Jiefei | |
| 245 | 0 | 0 |
_aTCR Repertoire Diversity of Peripheral PD-1 _h[electronic resource] |
| 260 |
_bCancer immunology research _c01 2020 |
||
| 300 |
_a146-154 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Immunological _xtherapeutic use |
| 650 | 0 | 4 |
_aB7-H1 Antigen _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aBiomarkers, Tumor _xanalysis |
| 650 | 0 | 4 |
_aCD8-Positive T-Lymphocytes _ximmunology |
| 650 | 0 | 4 |
_aCarcinoma, Non-Small-Cell Lung _xdrug therapy |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunotherapy _xmortality |
| 650 | 0 | 4 |
_aLung Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 |
_aProgrammed Cell Death 1 Receptor _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aReceptors, Antigen, T-Cell _xclassification |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aDuan, Jianchun | |
| 700 | 1 | _aBai, Hua | |
| 700 | 1 | _aWang, Yuqi | |
| 700 | 1 | _aWan, Rui | |
| 700 | 1 | _aWang, Xin | |
| 700 | 1 | _aChen, Si | |
| 700 | 1 | _aTian, Yanhua | |
| 700 | 1 | _aWang, Di | |
| 700 | 1 | _aFei, Kailun | |
| 700 | 1 | _aYao, Zhuoran | |
| 700 | 1 | _aWang, Shuhang | |
| 700 | 1 | _aLu, Zhimin | |
| 700 | 1 | _aWang, Zhijie | |
| 700 | 1 | _aWang, Jie | |
| 773 | 0 |
_tCancer immunology research _gvol. 8 _gno. 1 _gp. 146-154 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1158/2326-6066.CIR-19-0398 _zAvailable from publisher's website |
| 999 |
_c30305083 _d30305083 |
||